Related Experiment Video
Updated: Sep 16, 2025
05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
22.0K
Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke
Chunrong Tao1, Tianlong Liu1, Tao Cui2
1Department of Neurology, First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
The New England Journal of Medicine
|July 5, 2025
Summary
Early tirofiban treatment improved functional outcomes in acute ischemic stroke patients receiving thrombolysis. This study found a higher likelihood of excellent recovery with tirofiban, though with a slightly increased risk of hemorrhage.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Pharmacology
Background:
- Intravenous thrombolysis is a standard acute ischemic stroke treatment.
- Vascular reocclusion post-thrombolysis is a concern.
- Tirofiban, a glycoprotein IIb-IIIa inhibitor, shows promise in preventing reocclusion.
Purpose of the Study:
- To evaluate the efficacy and safety of early tirofiban administration in acute ischemic stroke patients.
- To determine if tirofiban improves functional outcomes after thrombolysis.
Main Methods:
- Phase 3, multicenter, double-blind, randomized, placebo-controlled trial.
- 414 patients received tirofiban, 418 received placebo intravenously within 60 minutes after thrombolysis.
- Primary outcome: excellent functional outcome (modified Rankin scale 0-1) at 90 days.
Main Results:
- Higher percentage of patients in the tirofiban group achieved excellent functional outcome (65.9% vs. 54.9%).
- Symptomatic intracranial hemorrhage occurred in 1.7% of tirofiban recipients versus 0% in placebo.
- 90-day mortality was similar between groups (4.1% vs. 3.8%).
Conclusions:
- Early tirofiban administration enhances the likelihood of excellent functional outcomes in acute ischemic stroke patients undergoing thrombolysis.
- While the incidence of intracranial hemorrhage was low, it was higher in the tirofiban group.
- Tirofiban represents a potential adjunctive therapy to improve stroke recovery.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
26
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
26
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
46
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
46
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
919
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
919
01:16Clot Retraction and Fibrinolysis
6.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.9K
01:28Acute Coronary Syndrome IV: Interprofessional Care
32
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
32
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K